ACLARION INC
ACONNASDAQTrading Snapshot
- Day Range
- $2.38 – $2.46
- 52-Week Range
- $1.95 – $12.03
- Volume
- $3.35B
- Avg Volume
- $2.41B
- Shares Outstanding
- 533,308
- Next Earnings
- Dec 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $75,730
- Last Q Revenue
- $25,208
- P/E Ratio
- -0.3
- P/S Ratio
- 16.5x
- EPS (TTM)
- $-3.74
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +41400.5%
Why Investors Own ACON
- ✓High-growth profile — revenue up -2.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ACLARION INC
ACON
StockOtter · stockotter.spaceAbout ACLARION INC
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical research CLARITY is a prospective, randomized
Aclarion, Inc. (NASDAQ:ACON) Short Interest Update
Aclarion, Inc. (NASDAQ: ACON - Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 76,007 shares, an increase
Reviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON)
OptimizeRx (NASDAQ: OPRX - Get Free Report) and Aclarion (NASDAQ: ACON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strengt
Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
PR Audio: BROOMFIELD, Colo., August 20, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
BROOMFIELD, Colo., August 12, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates
Aclarion, Inc. (ACON) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $2.75 per share a year ago.